Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

Matching the efficacy of Lilly’s Mounjaro and Novo’s Wegovy are “table stakes” for would-be competitors in the fast-evolving field, Metsera CEO Clive Meanwell told BioPharma Dive.